About us
Connect Biotech’s mission is to give biotech analysts and investors a refined yet expansive form of communication and relationship management.
Founded in July 2009, ConnectBiotech.org (CB) is a social utility that helps people communicate more efficiently with friends, colleagues and coworkers in the biotech community. CB wants to emphasize that relationships matter in the business world, and that is why new members join every day. Our website enables new relationships to be created and old ones rekindled with the latest technology.
When you join, you create a profile that summarizes your interest in the biotechnology field. From there you can invite trusted contacts, or search our database to see if they are already a member. CB enables any profile member the access to all profiles who haven’t been made private. So not only can you connect to your connections, and your connections’ connections, you can also be in contact with someone across the world who is looking to communicate with someone in your field. Through your network you can:
  • Manage the information that is publicly available
  • Find and be introduced to potential valuable connections
  • Publicize conference calls, or interviews you think are pertinent
  • Be found for business opportunities and find potential partners
  • Create Groups to interact in a smaller environment
  • Post and distribute job listings, polls, forum posts, blogs, and newsletters
  • Search our databse for companies and information about them
Copyright © 2014 connectbiotech.org.
Meet members from:
Zogenix, Inc.
Acceleron Pharma, Inc.
AdvanDx, Inc.
AbGenomics International Inc.
Spartan Bioscience Inc.
Southern Lights Biomaterials (SLB)
Nextrials, Inc.
Intralink-Spine Inc.
MagForce Nanotechnologies AG
GlaxoSmithKline plc (GSK)
TDC Medical, Inc.
InVivo Therapeutics
MethylGene Inc
Hamilton Thorne Biosciences, Inc.
QuantuMDx Group Limited
BioDiem Ltd
Pharmatek Laboratories, Inc.
BioSante Pharmaceuticals, Inc.
Vichem Chemie Ltd.
Glenveigh Medical, LLC
Xbrane Bioscience AB
... and many more.